Profiles and influencing factors of pulmonary fibrosis associated with biologic and conventional disease-modifying antirheumatic drugs for autoimmune diseases: a disproportionality study based on FAERS and VigiAccess
This study revealed varying degrees of pulmonary fibrosis signals related to DMARDs, with significantly overreporting observed in certain conventional and biologic DMARDs. Age was identified as a key susceptibility factor. As the use of these agents expands, clinicians should remain vigilant in monitoring for pulmonary fibrosis.
Authors
- Jiayi He (ORCID: https://orcid.org/0009-0001-1461-5714)
- Cheng Luo (ORCID: https://orcid.org/0000-0003-3864-8382)
- Qian Chen (ORCID: https://orcid.org/0000-0002-3011-3722)
- Nan Jia (ORCID: https://orcid.org/0000-0001-8685-9526)
- Xinhui Wu (ORCID: https://orcid.org/0000-0003-1195-5470)
- C. Y. Yang (ORCID: https://orcid.org/0000-0002-0478-1073)
- Fei Wang (ORCID: https://orcid.org/0000-0002-8158-0742)
- Xinyue Zhang (ORCID: https://orcid.org/0009-0005-5743-8649)
Institutions
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.3389/fphar.2025.1604895
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- World Health Organization
- National Natural Science Foundation of China